Stock listing

ASX:MX1 Micro-X Ltd. Share Price

Home listing (ASX) of Micro-X Ltd.

Follow Micro-X Ltd. into a list and get an email when it puts out news.

Share price · ASX:MX1

$0.029 AUD 0.000 (0.0%)

Close on Nov 20, 2026

Past year -67.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.029 – $0.029 AUDNov 20, 2026
Volume
308,550 sharesNov 20, 2026
Market cap
$21.83M AUDAt the close on Nov 20, 2026 · price × 752.9M shares outstanding
52-week range
$0.014 – $0.105 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$77,228 AUDMedian day 956,144 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Micro-X Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:MX1 · Home$0.029 AUD0.000 (0.0%)308,550$0.029$0.029$0.029$0.029Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:MX1 · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0290.0000.0%$0.029$0.029$0.029308,550
$0.029+0.001+3.6%$0.030$0.030$0.028250,932
$0.0280.0000.0%$0.028$0.028$0.028200,000
$0.028-0.002-6.7%$0.031$0.032$0.028659,918
$0.0300.0000.0%$0.030$0.031$0.029294,026
$0.0300.0000.0%$0.029$0.031$0.0281,197,676
$0.0300.0000.0%$0.034$0.034$0.030260,058
$0.0300.0000.0%$0.029$0.030$0.029742,086
$0.030-0.001-3.2%$0.032$0.032$0.0301,151,099
$0.031-0.002-6.1%$0.032$0.032$0.0311,133,523
$0.033+0.001+3.1%$0.033$0.033$0.033165,561
$0.0320.0000.0%$0.035$0.038$0.0321,556,512
$0.0320.0000.0%$0.032$0.032$0.030346,132
$0.032-0.004-11.1%$0.034$0.035$0.030944,974
$0.036-0.003-7.7%$0.039$0.039$0.0331,457,171
$0.0390.0000.0%$0.039$0.040$0.039498,548
$0.039-0.004-9.3%$0.046$0.046$0.039388,776
$0.043+0.002+4.9%$0.042$0.045$0.040596,790
$0.041-0.011-21.2%$0.053$0.053$0.0401,106,141
$0.052-0.006-10.3%$0.058$0.058$0.052661,128
$0.0580.0000.0%$0.060$0.064$0.0581,672,663
$0.058+0.002+3.6%$0.058$0.059$0.05668,156
$0.056-0.004-6.7%$0.060$0.060$0.055859,273
$0.060+0.002+3.4%$0.058$0.065$0.0572,565,137
$0.058-0.003-4.9%$0.060$0.062$0.0581,139,896
$0.061-0.001-1.6%$0.064$0.065$0.0571,970,133
$0.062+0.002+3.3%$0.059$0.067$0.0533,881,506
$0.060-0.003-4.8%$0.064$0.064$0.056891,084
$0.063-0.001-1.6%$0.066$0.066$0.062690,525
$0.064+0.010+18.5%$0.055$0.077$0.0539,775,957
$0.054+0.003+5.9%$0.051$0.054$0.051241,960
$0.051-0.003-5.6%$0.051$0.054$0.051345,657
$0.054-0.001-1.8%$0.055$0.058$0.0541,716,994
$0.055-0.007-11.3%$0.063$0.063$0.0551,444,715
$0.062-0.001-1.6%$0.063$0.069$0.0621,616,079
$0.063+0.006+10.5%$0.060$0.072$0.0558,017,336
$0.057+0.008+16.3%$0.048$0.091$0.04818,027,612
$0.049+0.008+19.5%$0.045$0.054$0.0415,520,705
$0.041-0.004-8.9%$0.048$0.054$0.0412,031,650
$0.045+0.004+9.8%$0.041$0.047$0.038967,313
$0.041-0.007-14.6%$0.049$0.053$0.0413,049,495
$0.048+0.018+60.0%$0.031$0.054$0.0314,751,168
$0.030+0.005+20.0%$0.026$0.033$0.0262,733,907
$0.025+0.007+38.9%$0.019$0.026$0.0191,104,026
$0.018+0.001+5.9%$0.017$0.021$0.017731,478
$0.017+0.003+21.4%$0.015$0.017$0.0154,345,202
$0.014-0.001-6.7%$0.016$0.017$0.0142,788,324
$0.015-0.003-16.7%$0.018$0.018$0.0153,043,936
$0.018-0.001-5.3%$0.020$0.020$0.0181,269,266
$0.019+0.001+5.6%$0.022$0.022$0.018979,009
$0.018+0.001+5.9%$0.018$0.019$0.0161,670,183
$0.017-0.003-15.0%$0.020$0.020$0.0172,485,704
$0.020-0.001-4.8%$0.021$0.022$0.019674,774
$0.021-0.001-4.5%$0.021$0.022$0.021224,389
$0.022-0.003-10.2%$0.024$0.024$0.0212,293,973
$0.025-0.001-5.8%$0.025$0.025$0.024406,067
$0.026+0.001+4.0%$0.025$0.026$0.025293,438
$0.025-0.002-7.4%$0.027$0.027$0.0251,121,203
$0.027+0.002+8.0%$0.026$0.027$0.02679,046
$0.025-0.001-3.8%$0.026$0.029$0.025673,923
$0.0260.0000.0%$0.027$0.027$0.026495,362
$0.0260.0000.0%$0.027$0.027$0.026314,180
$0.0260.0000.0%$0.027$0.028$0.026146,019
$0.026-0.001-3.7%$0.027$0.027$0.026360,133
$0.0270.0000.0%$0.027$0.027$0.027741
$0.0270.0000.0%$0.027$0.028$0.027809,772
Ticker
ASX:MX1
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Micro-X Ltd. news

Micro-X Ltd. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
51 in the last 12 months · 182 in all · newest Nov 12, 2026 · oldest 2016
Decks
39 decks · latest Nov 4, 2026

Where Micro-X Ltd. is listed

ListingExchangeCountryCurrency
ASX:MX1 · Home listing · This pageASXAustraliaAUD
OTC:MCRXFOTCUnited StatesUSD

Cash and shares

Jun 2026 deck · Micro-X — Investor Presentation (June 2026)

Cash
$3.5 million

The slide these figures come from

Valuation

EV/sales 1.7× against a median of 0.8×: 6th lowest of 10 Medical devices & supplies companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$25.18M AUD
P/E
Loss
EV/sales
1.7×
EV/EBITDA
Negative EBITDA
Price/book
4.5×
Gross margin
−60.7%
Operating margin
−104.7%
Net margin
−65.5%
Debt to equity
1.3×
Beta
No index for this market yet

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Micro-X Ltd. · ASX:MX1US$14.45MUS$16.66Mn/a1.7×n/a4.5×−65.5%1.3×n/a
Picard Medical, Inc. · AMEX:PMIUS$15.88MUS$17.30Mn/a3.3×n/a11.9×−371.7%1.1×0.41
SG Healthcare Co., Ltd. · KRX:398120US$15.78MUS$11.93M19.3×0.6×n/a0.9×4.2%0.0×n/a
Careplus Group Bhd. · MYX:CAREPLSUS$15.50MUS$20.64Mn/a0.8×n/a0.3×−11.1%0.1×n/a
HeartBeam, Inc. · NASDAQ:BEATUS$15.50MUS$9.44Mn/an/an/a2.4×n/a0.0×1.93
Lifecare ASA · OSL:LIFEUS$15.21MUS$11.43Mn/a175×n/a2.7×n/a0.0×n/a
Control Bionics Ltd. · ASX:CBLUS$15.13MUS$14.16Mn/a4.5×n/a3.6×−152.4%0.1×n/a
Perimeter Medical Imaging AI Inc · TSXV:PINKUS$14.45MUS$8.00Mn/a3.8×n/a3.5×−478.7%0.0×1.55
CVRx, Inc. · NASDAQ:CVRXUS$14.27MUS$14.18Mn/a0.2×n/a1.0×−88.3%4.2×1.28
Suzhou Basecare Medical Corp. Ltd. Class H · HKEX:2170US$13.52MUS$8.12Mn/a0.2×n/a0.1×−66.8%0.4×n/a
CytoSorbents Corporation · NASDAQ:CTSOUS$13.12MUS$26.43Mn/a0.7×n/an/a−46.7%n/a1.42
Median of the othersUS$15.17MUS$13.05M19.3×0.8×2.4×−77.5%0.1×1.42

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
0.060 AUD · Analysts' mean
EPS, year to Jun 2027
-0.007 · 1 analyst
Revenue, year to Jun 2027
22.96M · 1 analyst

Team and board

Officers

OfficerRole
Brian GonzalesChief Executive Officer
Kingsley HallCEO
Peter DickmanChief Financial Officer
Anthony SkeatsChief Operating Officer

Board

DirectorRole
Patrick O’BrienNon-Executive Chair
Andrew HartmannNon-Executive Director
Ilona MeyerNon-Executive Director
Jim McDowellNon-Executive Director

Events

QuarterResultsShare move
Quarter to Mar 31, 2026Apr 28, 2026−3.5%
Quarter to Sep 30, 2025Dec 3, 2025+3.7%
Q4 2025Aug 28, 2025 · Before open−2.5%
Quarter to Mar 31, 2025May 30, 2025−3.5%
Q2 2025Feb 28, 2025−3.0%
Quarter to Sep 30, 2024Nov 27, 2024−6.6%
Q4 2024Aug 27, 2024−7.7%
Quarter to Mar 31, 2024Jun 11, 2024 · After close0.0%
Q2 2024Feb 27, 2024−4.2%
Quarter to Sep 30, 2023Oct 27, 2023 · After close+7.7%
All 19 quarters
QuarterResultsShare move
Q4 2023Aug 30, 2023 · Before open+4.2%
Q3 2023Apr 27, 2023 · After close0.0%
Q2 2023Feb 26, 2023 · After close−3.7%
Q1 2023Nov 30, 20220.0%
Q4 2022Aug 29, 2022 · After close−9.4%
Q3 2022Apr 25, 2022+5.1%
Q2 2022Feb 23, 2022 · After close−17.5%
Q4 2021Aug 26, 2021 · After close+3.8%
Q2 2021Feb 24, 2021 · After close−1.3%

Open Events

Decks

DeckKindSlidesDate
Q1 FY27 Earnings PresentationEarnings17 slidesNov 4, 2026
Investor Presentation (August 2026)Investor deck27 slidesAug 3, 2026
Investor Presentation (June 2026)Investor deck23 slidesJun 25, 2026
HealthInvest, Sydney 2026Conference12 slidesJun 3, 2026
H1 FY2026 Earnings PresentationEarnings33 slidesFeb 27, 2026
Investor Presentation (December 2025)Investor deck35 slidesDec 18, 2025
Shareholder Meeting (November 2025)Shareholder meeting18 slidesNov 11, 2025
FY2025 Earnings PresentationEarnings24 slidesAug 28, 2025
Non-Deal Roadshow (July 2025)Roadshow24 slidesJul 30, 2025
H1 FY2025 Earnings PresentationEarnings24 slidesFeb 28, 2025
All 39 decks
DeckKindSlidesDate
Investor Presentation (December 2024)Investor deck22 slidesDec 10, 2024
Shareholder Meeting (November 2024)Shareholder meeting14 slidesNov 12, 2024
FY2024 Earnings PresentationEarnings24 slidesAug 29, 2024
H1 FY2024 Earnings PresentationEarnings25 slidesFeb 28, 2024
Shareholder Meeting (December 2023)Shareholder meeting20 slidesDecember 2023
Bell Potter Healthcare Conference 2023Conference20 slidesNov 14, 2023
Bell Potter Healthcare Conference 2023Conference21 slidesNov 14, 2023
Corporate Update (August 2023)Corporate update21 slidesAug 7, 2023
Shareholder Meeting (November 2022)Shareholder meeting40 slidesNov 14, 2022
Shareholder Meeting (November 2022)Shareholder meeting20 slidesNov 14, 2022
Investor Presentation (March 2022)Investor deck31 slidesMar 21, 2022
Shareholder Meeting (November 2021)Shareholder meeting28 slidesNov 19, 2021
ShareCafe Investor Webinar (September 2021)Conference14 slidesSep 10, 2021
ShareCafé Small Caps "Hidden Gems" Webinar (September 2021)Conference15 slidesSep 9, 2021
Investor Presentation (July 2021)Investor deck19 slidesJul 29, 2021
Evans and Partners Investor Conference 2021Conference19 slidesMar 24, 2021
ASX Small and Mid-Cap Conference 2021Conference17 slidesMar 15, 2021
Shareholder Meeting (November 2020)Shareholder meeting36 slidesNov 18, 2020
Shareholder Meeting (November 2019)Shareholder meeting14 slidesNov 29, 2019
Bioshares Biotech Summit 2019Conference23 slidesJul 26, 2019
15th Bioshares Biotech Summit 2019Conference24 slidesJul 26, 2019
Shareholder Meeting (November 2018)Shareholder meeting15 slidesNov 21, 2018
2018 Australian MicroCap Investment ConferenceConference15 slidesOct 18, 2018
14th Bioshares Biotechnology Summit 2018Conference17 slidesJul 30, 2018
2018 Bioshares Biotechnology SummitConference16 slidesJul 28, 2018
Shareholder Meeting (October 2017)Shareholder meeting27 slidesOct 24, 2017
Investor Presentation (April 2017)Investor deck46 slidesApr 10, 2017
Corporate Update (March 2017)Corporate update7 slidesMar 22, 2017
Investor Presentation (December 2016)Investor deck35 slidesDec 6, 2016

Open Decks

Financings

RaiseDateIn US dollars
Unlisted secured convertible notes
Tranche closed: A$7M raised · TIGA Trading Pty Ltd
Dealers: TIGA Trading Pty Ltd
Buyers: Directors (subscriptions from Directors)
Insiders: Directors subscribed for convertible notes
Use of proceeds: Development and commercialisation of Head CT, commercial launch of updated Rover, operating costs and general working capital
Oct 9, 2026
Convertible notes
Update: up to A$8M · A$1 · TIGA Trading Pty Ltd
Dealers: TIGA Trading Pty Ltd
Buyers: Bindella Capital Pty Ltd (among investors issued 5,330,000 Notes with a face value of $5,330,000); Patrick O'Brien (up to 500,000 Notes); Ilona Meyer (up to 60,000 Notes); James McDowell (up to 100,000 Notes); Andrew Hartmann (up to 10,000 Notes); TIGA Trading Pty Ltd (underwrites 2,000,000 Notes with a face value of $2,000,000)
Insiders: Directors Patrick O'Brien, Ilona Meyer, James McDowell and Andrew Hartmann committed to subscribe for 670,000 Notes with a face value of $670,000, subject to shareholder approval
Use of proceeds: Head CT development and commercialisation, commercial launch of the updated Rover, operating costs, general working capital and transaction costs
Aug 27, 2026US$5.75M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue15.1M13.1M15.2M15.0M8.97M3.77M4.25M1.93M1.61M659.0K
Cost of revenue24.2M2.73M9.48M22.1M21.3M16.7M11.9M6.52M8.05M15.3M
Gross profit-9.15M10.3M5.74M-7.11M-12.3M-13.0M-7.69M-4.59M-6.44M-14.6M
Research and development12.0K12.0K59.0K720.0K420.0K7.41M121.0K
Selling, general and administrative19.4M18.0M17.4M17.8M16.7M10.9M1.47M1.67M1.44M890.0K
Operating income-15.8M-17.1M-13.0M-16.3M-19.8M-15.8M-11.7M-13.2M-13.2M-19.4M
Depreciation and amortization1.38M1.57M1.54M1.59M1.43M2.33M1.97M744.0K120.0K79.0K
EBITDA-14.4M-15.5M-11.5M-14.7M-18.3M-13.5M-9.72M-12.5M-13.1M-19.3M
Interest expense519.0K561.0K248.0K269.0K296.0K680.0K856.0K495.0K183.0K139.0K
Income before tax-15.5M-13.9M-9.77M-17.4M-20.7M-16.6M-12.1M-9.83M-16.6M-12.9M
Income tax-5.67M-5.43M-6.37M-6.65M-3.65M-1.89M-2.04M-3.08M-3.84M-7.05M
Net income-9.88M-13.9M-9.77M-10.8M-17.1M-14.7M-10.1M-9.83M-16.6M-12.9M
Earnings per share, basic-0.01-0.02-0.02-0.02-0.04-0.04-0.04-0.07-0.11-0.10

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents3.14M3.24M3.23M5.22M10.3M30.1M18.3M1.61M4.07M5.57M
Short-term investments04.00K4.00K
Receivables7.38M8.32M10.2M7.00M3.75M2.48M5.20M268.0K533.0K199.0K
Inventory4.02M4.27M5.38M7.34M5.78M2.84M1.81M1.27M1.55M1.20M
Current assets15.0M17.1M19.9M22.4M22.7M35.8M25.4M6.29M10.1M14.5M
Property, plant and equipment5.00M6.88M7.73M8.39M8.74M7.26M1.75M393.0K358.0K
Total assets19.7M22.1M26.9M30.3M31.3M44.7M33.7M9.87M14.7M25.7M
Accounts payable2.38M3.28M2.54M2.48M1.30M691.0K1.54M2.06M3.53M4.22M
Current liabilities11.3M11.3M8.63M8.32M6.48M4.31M8.74M7.59M10.2M10.2M
Long-term debt05.53M5.00M5.00M
Total debt6.48M6.53M3.99M4.77M5.38M5.90M12.6M13.0M9.60M3.00M
Total liabilities14.8M14.6M12.6M13.2M12.1M10.5M19.0M12.8M15.4M10.4M
Shareholders' equity4.91M7.55M14.3M17.1M19.2M34.1M14.7M-2.98M-727.0K15.3M
Shares outstanding698.8M610.3M527.2M495.8M460.3M398.1M231.6M151.1M144.4M123.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-8.92M-8.59M-6.43M-11.0M-18.1M-9.86M-9.46M-7.15M-7.84M-10.5M
Capital spending-144.0K-100.0K-369.0K-779.0K-1.11M-901.0K-2.20M-1.64M-155.0K-272.0K
Free cash flow-9.07M-8.69M-6.80M-11.8M-19.2M-10.8M-11.7M-8.79M-7.99M-10.8M
Cash from investing-144.0K-100.0K-369.0K-779.0K-1.11M-901.0K-2.20M-1.71M-267.0K-382.0K
Cash from financing8.96M8.71M4.81M6.69M-612.0K22.6M28.4M6.40M6.60M12.3M
Dividends paid-6.59M-22.1M-26.3M-2.22M-11.6M
Share buybacks-280.0K-355.0K-396.0K-105.0K-105.0K-1.99M-2.22M-2.22M0-672.0K
Change in cash-106.0K14.0K-2.00M-5.08M-19.8M11.8M16.7M-2.46M-1.50M1.40M

Open Financials

Filings

FilingDateTypeFiled with
MX1 - 2026 AGM Results of MeetingNov 11, 2026Meeting outcomeASX
Change in substantial holdingNov 11, 2026Ownership change noticeASX
MX1 - Quarterly Results PresentationNov 3, 2026Quarterly reportASX
MX1 - Quarterly Activities Report & Appendix 4COct 29, 2026Quarterly reportASX
MX1 - Quarterly Activities Report & Appendix 4COct 29, 2026Quarterly reportASX
MX1 - Notice Under Section 708A(5) of the Corporations ActOct 23, 2026Other filingsASX
Application for quotation of securities - MX1Oct 23, 2026FinancingASX
Notification of cessation of securities - MX1Oct 23, 2026FinancingASX
MX1 - Notice of 2026 Annual General Meeting and Proxy FormOct 14, 2026Meeting noticeASX
Change of Director's Interest Notice - Patrick O'BrienOct 8, 2026Ownership change noticeASX
All 181 filings
FilingDateTypeFiled with
Change of Director's Interest Notice - Andrew HartmannOct 8, 2026Ownership change noticeASX
Change of Director's Interest Notice - Jim McDowellOct 8, 2026Ownership change noticeASX
Change of Director's Interest Notice - Ilona MeyerOct 8, 2026Ownership change noticeASX
Notification regarding unquoted securities - MX1Oct 8, 2026Other filingsASX
MX1 - Convertible Note Funding UpdateOct 8, 2026FinancingASX
MX1 - Results of MeetingSep 28, 2026Meeting outcomeASX
MX1 - DHS CT Baggage Scanner Contract ExtensionSep 27, 2026Other filingsASX
MX1 - Change of Director's Interest Notice - Patrick O'BrienSep 24, 2026Ownership change noticeASX
Response to ASX Price QuerySep 23, 2026Explanation requestASX
MX1 - Investor Open Day Presentation RecordingSep 9, 2026Other filingsASX
Notification of cessation of securities - MX1Sep 9, 2026FinancingASX
MX1 - Notice Under Section 708A(5) of the Corporations ActSep 9, 2026Notification letterASX
Application for quotation of securities - MX1Sep 9, 2026FinancingASX
Ceasing to be a substantial holderSep 3, 2026Ownership change noticeASX
MX1 - 2026 Appendix 4E and Annual ReportAug 27, 2026Annual reportASX
MX1 - Notice of General Meeting and Proxy FormAug 27, 2026Meeting noticeASX
MX1 - 2026 Appendix 4G and Corporate Governance StatementAug 27, 2026Other filingsASX
MX1 - Investor Open DayAug 18, 2026Meeting noticeASX
Notification of cessation of securities - MX1Aug 14, 2026FinancingASX
MX1 - Notice Under Section 708A(5) of the Corporations ActAug 14, 2026Other filingsASX
Application for quotation of securities - MX1Aug 14, 2026FinancingASX
MX1 - Notice Under Section 708A(5) of the Corporations ActAug 12, 2026FinancingASX
Notification regarding unquoted securities - MX1Aug 12, 2026Other filingsASX
Change in substantial holdingAug 6, 2026Ownership change noticeASX
MX1 - Investor PresentationAug 2, 2026Other filingsASX
MX1 - Management Update & Convertible Note IssueAug 2, 2026FinancingASX
Proposed issue of securities - MX1Aug 2, 2026FinancingASX
MX1 - Quarterly Activities Report & Appendix 4CJul 31, 2026Quarterly reportASX
MX1 - Micro-X Completes Full Body CT Critical Design ReviewJun 9, 2026Other filingsASX
MX1 - Human Imaging Study Commences with Micro-X Head CTJun 2, 2026Operations updateASX
$1.3m Checkpoint Contract Extension Awarded by DHSMay 18, 2026Other filingsASX
MX1 - First Full Body CT Laboratory Test Bench CompletedMar 9, 2026Operations updateASX
MX1 - December 2025 Half Year Results PresentationFeb 26, 2026Interim reportASX
MX1 - Appendix 4D and Half Year Financial StatementsFeb 26, 2026Interim reportASX
MX1 - Response to Publication on Government WebsiteFeb 22, 2026Other filingsASX
MX1 - Head CT First Human Pilot Site at Royal MelbourneFeb 3, 2026Operations updateASX
MX1 - Quarterly Activities Report & Appendix 4CJan 29, 2026Quarterly reportASX
MX1 - $6m Capital Raising PresentationDec 17, 2025FinancingASX
MX1 - $6.18m PlacementDec 17, 2025FinancingASX
Trading HaltDec 15, 2025Trading halt or suspensionASX
MX1 - Micro-X Receives $5.1 Million R&D Tax IncentiveOct 6, 2025Other filingsASX
MX1 - $3.3M Rover Plus Order from Malaysian MOHOct 2, 2025Acquisition or disposalASX
MX1 - Head CT Milestone - Proceeding to Imaging TrialSep 30, 2025Operations updateASX
MX1 - $2.5M Checkpoints Contract Extension with DHSSep 23, 2025Other filingsASX
MX1 - $4.4M IGP Grant Received for Head CTSep 23, 2025Operations updateASX
MX1 - 2025 Full Year Results PresentationAug 27, 2025ResultsASX
MX1 - 2025 Appendix 4E and Annual ReportAug 27, 2025Annual reportASX
MX1 - Supply Agreement with Major US Healthcare ProviderJul 29, 2025Acquisition or disposalASX
MX1 - Micro-X Achieves $2.3m of Development MilestonesJun 16, 2025Other filingsASX
MX1 - Appendix 4C and Quarterly Activities StatementApr 28, 2025Quarterly reportASX
MX1 - Result of Entitlement OfferMar 19, 2025FinancingASX
MX1 - December 2024 Half Year Results PresentationFeb 28, 2025Interim reportASX
MX1 - Appenxix4D and Half Year Financial StatementsFeb 28, 2025Interim reportASX
MX1 - Extension of Retail Entitlement OfferFeb 24, 2025Offer documentASX
MX1 - $6.0M DHS Contract ExtensionFeb 13, 2025Other filingsASX
MX1 - Retail Offer BookletFeb 12, 2025Offer documentASX
MX1 - $2.7M Retail Offer OpensFeb 12, 2025FinancingASX
MX1 - $3.3M raised through Placement and Institutional OfferFeb 9, 2025FinancingASX
Reinstatement to Official QuotationFeb 9, 2025Trading halt or suspensionASX
MX1 - $6M Capital RaiseFeb 6, 2025FinancingASX
MX1 - $5.6M Strategic PartnershipFeb 5, 2025Other filingsASX
Voluntary SuspensionFeb 3, 2025Trading halt or suspensionASX
MX1 - Quarterly Cash Flows and Activities StatementJan 31, 2025Quarterly reportASX
MX1 - $6.4M R&D Incentive receivedDec 5, 2024ResultsASX
MX1 - Portable Full Body CT Decvelopment AgreementDec 3, 2024Operations updateASX
MX1 - US Government Development ContractDec 3, 2024Other filingsASX
Pause in TradingDec 2, 2024Trading halt or suspensionASX
MX1 - 2024 AGM Chair's AddressNov 12, 2024Other filingsASX
MX1 - 2024 AGM - CEO PresentationNov 12, 2024Other filingsASX
MX1 - 2024 Full Year Results PresentationAug 28, 2024ResultsASX
MX1 - 2024 Appendix 4E and Annual ReportAug 28, 2024Annual reportASX
MX1 - Results of Share Purchase PlanMay 27, 2024FinancingASX
MX1 - Quarterly Cash Flow and Activities StatementApr 28, 2024Quarterly reportASX
MX1 - Prospectus lodgementApr 24, 2024Offer documentASX
Micro-X completes $4M Placement and announces SPPApr 16, 2024FinancingASX
MX1 - December 2023 Half Year Results PresentationFeb 27, 2024Interim reportASX
MX1 - Appendix 4D & Half Year Financial StatementsFeb 27, 2024Interim reportASX
MX1 - Quarterly Cashflows and Activity StatementJan 29, 2024Quarterly reportASX
MX1 - Rover receives CE Mark certificationOct 26, 2023Operations updateASX
MX1 - Receipt of $6.2M R&D Tax RebateOct 22, 2023ResultsASX
MX1 - $1.5M Rover order from Australian GovernmentSep 19, 2023Operations updateASX
MX1 - Appendix 4E and Annual Financial StatementsAug 29, 2023Annual reportASX
MX1 - Strategy Refresh PresentationAug 6, 2023Other filingsASX
MX1 - DHS Airport Security Contract - up to $21MJul 23, 2023Other filingsASX
Response to ASX QueryMay 30, 2023Explanation requestASX
MX1 - Leadership Transition - Kingsley Hall appointed CEOMay 1, 2023Other filingsASX
MX1 - Quarterly Cash Flow and Activities ReportApr 26, 2023Quarterly reportASX
MX1 - 2022 AGM CEO PresentationNov 14, 2022Other filingsASX
MX1 - 2022 AGM Chairs AddressNov 14, 2022Other filingsASX
MX1 - Quarterly Cashflow and Activities StatementOct 25, 2022Quarterly reportASX
MX1 - DHS Contract Extensions AwardedSep 25, 2022Other filingsASX
MX1 - $15M Strategic Investment and CollaborationSep 19, 2022Other filingsASX
Mx1 - Amended Auditors ReportSep 2, 2022Other filingsASX
MX1 - Appendix 4E and 2022 Annual Financial ReportAug 29, 2022Annual reportASX
MX1 - Amended Quarterly Cash Flows and Activity ReportAug 1, 2022Quarterly reportASX
MX1 - Appointment of second major US DistributorJun 13, 2022Other filingsASX
MX1 - Appendix 4D and Half Yearly ReportFeb 23, 2022Interim reportASX
MX1 - Amended Quarterly Cash Flows and Activities StatementJan 27, 2022Quarterly reportASX
MX1 - Receipt of $2.1M R&D RebateDec 21, 2021Other filingsASX
MX1 - US Govt DHS Baggage X-ray Development contract signedSep 29, 2021Other filingsASX
MX1 - US Govt DHS Airport Security Portal contract signedSep 29, 2021Other filingsASX
MX1 - $8M contract signed with Australian Stroke AllianceSep 23, 2021Other filingsASX
MX1 - Rover receives ARTG listingSep 13, 2021Other filingsASX
MX1 - Appendix 4E and 2021 Annual Financial ReportAug 26, 2021Annual reportASX
MX1 - Rover FDA approval opens US Healthcare MarketMay 25, 2021Other filingsASX
MX1 Quarterly Cash Flows and Activity StatementApr 12, 2021Quarterly reportASX
MX1 - Market Update - Thales Settlement and IED X-ray cameraMar 15, 2021Other filingsASX
MX1 - Successful MRFF Funding AwardFeb 28, 2021Other filingsASX
MX1 - Appendix 4D and Half Year Financial ReportFeb 24, 2021Interim reportASX
Micro-X - SPP Offer OpenFeb 3, 2021Other filingsASX
Micro-X completes $30.5M Placement and announces SPPJan 31, 2021FinancingASX
MX1 Quarterly Activities and Cash Flow ReportJan 19, 2021Quarterly reportASX
MX1 - Receipt of $1.95M R&D RebateJan 7, 2021Other filingsASX
MX1 - $1.3M Rover contract with Australia Defence ForceDec 17, 2020Other filingsASX
Micro-X Amended Nano Distribution AgreementNov 18, 2020Other filingsASX
Market Update DHS US$4M Airport Security AwardNov 3, 2020Other filingsASX
Micro-X Quarterly Cash Flow and Activities StatementOct 21, 2020Quarterly reportASX
Micro-X Market update - First Sale of RoverSep 30, 2020Other filingsASX
Appendix 4E and 2020 Annual Financial ReportAug 27, 2020Annual reportASX
Appendix 4C - quarterlyJul 21, 2020Quarterly reportASX
Micro-X Receives Rover FDA 510(k) ApprovalJul 19, 2020Other filingsASX
Micro-X Market Update - Submission of Rover FDA 510 (k)Jun 10, 2020Other filingsASX
Market update - Micro-X Rover Testing CompleteJun 1, 2020Other filingsASX
Micro - X - Nano shipment and reduction in backlogMay 29, 2020Other filingsASX
Micro-X Market Update Nano Production IncreasingMay 12, 2020Other filingsASX
Micro-X Results of Entitlement OfferMay 11, 2020FinancingASX
Micro-X - $15M Placement & Underwritten Entitlement OfferApr 17, 2020FinancingASX
Non Renounceable Entitlement Offer ProspectusApr 16, 2020FinancingASX
Quarterly Activities & Cash Flow ReportApr 7, 2020Quarterly reportASX
Market UpdateMar 25, 2020Other filingsASX
Appendix 4D & Half-Year Financial ReportFeb 13, 2020Interim reportASX
Quarterly Cash Flow & Business UpdateJan 30, 2020Quarterly reportASX
Lodgement of ProspectusNov 19, 2019Offer documentASX
Micro-X $16.5M Private PlacementNov 18, 2019FinancingASX
MARKET UPDATENov 15, 2019Other filingsASX
Suspension from Official QuotationNov 5, 2019Trading halt or suspensionASX
CARBON NANOTUBE EMITTER PATENT PUBLISHEDOct 20, 2019Other filingsASX
UK Government Follow-On Airport Security ContractSep 5, 2019Other filingsASX
Appendix 4E and 2019 Annual ReportAug 30, 2019Annual reportASX
Federal Court Orders GrantedJul 25, 2019Legal or regulatory actionASX
Next Generation Proprietary CNT X-ray Tubes InsourcedJul 14, 2019Other filingsASX
COMPLETION OF $10M INVESTMENT BY THALES SAJul 2, 2019Other filingsASX
Cleansing NoticeMay 28, 2019FinancingASX
Trading haltMay 23, 2019Trading halt or suspensionASX
Pause in tradingMay 22, 2019Trading halt or suspensionASX
MICRO-X SIGNS ALLIANCE WITH THALES GROUPMar 31, 2019Other filingsASX
Appendix 4D and Half-Year Financial ReportFeb 28, 2019Interim reportASX
COMPLETION OF CAPITAL RAISEDec 24, 2018Other filingsASX
SUCCESSFUL COMPLETION OF $3.0M CAPITAL RAISEOct 1, 2018Other filingsASX
R&D Tax RebateSep 17, 2018Other filingsASX
Appendix 4E and 2018 Annual ReportAug 29, 2018Annual reportASX
EXPECTED IMPAIRMENT CHARGE CLARIFICATIONAug 15, 2018Other filingsASX
EXPECTED IMPAIRMENT CHARGEAug 13, 2018Other filingsASX
R&D CONTRACT SIGNED WITH UK MINISTRY OF DEFENCEApr 26, 2018Other filingsASX
SUCCESSFUL COMPLETION OF $5.0M CAPITAL RAISINGMar 27, 2018FinancingASX
NANO COMMERCIALISATION UPDATEMar 6, 2018Other filingsASX
Appendix 4D and Half Year Financial ReportFeb 28, 2018Interim reportASX
Nano Commercialisation - First From Production AcceptanceOct 4, 2017Other filingsASX
Appendix 4E and 2017 Annual ReportAug 30, 2017Annual reportASX
R&D TAX REBATEAug 29, 2017Other filingsASX
Carestream receives FDA 510(k) Approval for NanoJun 25, 2017Other filingsASX
SUCCESSFUL COMPLETION OF $4.8M ENTITLEMENT OFFERMay 5, 2017FinancingASX
Micro-X Entitlement Offer now fully underwrittenApr 12, 2017FinancingASX
Entitlement OfferApr 9, 2017FinancingASX
Nano Commercialisation Update - K number received from FDAMar 14, 2017Other filingsASX
Nano Commercialisation Update - ISO 13485 AccreditationMar 5, 2017Other filingsASX
Nano Commercialisation UpdateNov 27, 2016Other filingsASX
Appendix 4E and 2016 Annual ReportAug 31, 2016Annual reportASX
Micro-X & Carestream Sign Development and Supply AgreementsAug 28, 2016Other filingsASX
Micro-X makes US$4 Million Investment in Xinray Systems Inc.Feb 11, 2016Other filingsASX
ASX Market Release - Admission to Official ListFeb 10, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from Micro-X Ltd.’s releases · as of Oct 9, 2026

Common shares
752,872,169
Fully diluted
752,872,169

Fully diluted

LineShares
Common shares752,872,169

Share count over time

CountShares
Nov 22, 2026752,872,169

Open Cap table

Shareholders

StakeStakeSharesDateFiling
Acorn Capital Limited8.72%65.7MNov 10, 2026Substantial holder notice (ASX forms 603, 604, 605)

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrew HartmannNon-Executive Director · Since at least Nov 5, 2026
Anthony SkeatsChief Operating Officer · Since at least Nov 4, 2026
Brian GonzalesChief Executive Officer · Since at least Nov 5, 2026
Ilona MeyerNon-Executive Director · Since at least Nov 5, 2026
Jim McDowellNon-Executive Director · Since at least Nov 5, 2026
Kingsley HallCEO · Since at least Nov 26, 2025
Patrick O’BrienNon-Executive Chair · Since at least Nov 5, 2026
Peter DickmanChief Financial Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Micro-X Ltd.